When will the first RISUG procedure become commercially available?
RégulationOne-OffSanté et médecine4aManifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelle2035 or later 55.2%En tête parmi 11 options
Prévisionnistes
2
Type de question
multiple choice
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Variation 7j
0.0 pts
Données du marché
Mis à jour il y a 7 heures
Obsolète30 juin 25, 13:25 UTC30 déc. 30, 14:21 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
In what year will Tesla's robotaxi become commercially operational in the US?
Manifold MarketsWill there be a commercially available LLM-based self-driving system by EoY 2030?
Manifold MarketsWill a useful contact lens display be commercially available by 2030
Manifold MarketsWill we have AGI before commercially available and viable flying cars???
Manifold MarketsWill all covid vaccines be pulled off the market before 2030?
Manifold MarketsWhich engineering breakthroughs will achieve widespread commercial and societal integration by 2050? [add responses]
Manifold MarketsRègles
Resolution Criteria
- This market will resolve to the first year in which the Reversible Inhibition of Sperm Under Guidance (RISUG) procedure becomes commercially available to the general public. "Commercially available" is defined as the procedure being offered by licensed medical practitioners outside of clinical trial settings, with necessary regulatory approvals in place.
- The resolution will be based on official announcements from regulatory bodies or reputable medical institutions confirming the availability of RISUG for public use.
- RISUG is a non-hormonal male contraceptive developed in India, involving an injection into the vas deferens to block sperm transport.
- Clinical trials have demonstrated its efficacy and safety, with a reported 97% success rate in preventing pregnancy.
- As of 2023, RISUG has completed Phase III clinical trials in India and is awaiting regulatory approval from the Drug Controller General of India (DCGI).
